CAMBROOKE THERAPEUTICS INTERNATIONAL LIMITED – HE 345621 (the Disappearing Company), a private limited liability company duly incorporated and validly existing under the laws of Cyprus, intends to proceed with a restructuring by means of a cross-border merger (the Cross-Border Merger) by which the Disappearing Company will be fully merged into and absorbed by NUALTRA LIMITED (the Surviving Company), a private limited liability company duly incorporated and validly existing under the laws of Ireland with registration number 516122 and having its registered office at Roselawn Suite 1, Roselawn House, National Technology, Park Limerick, Co. Limerick, Limerick, Ireland.
The Disappearing Company and the Surviving Company are sister companies, both wholly owned by Ajinomoto Cambrooke, Inc., a corporation incorporated under the laws of the State of Massachusetts, having its registered office at 4, Copeland Drive, Ayer, 01432, Massachusetts, United States of America.
The Common Draft Terms of Cross-Border Merger (the Cross-Border Merger Plan) and other relevant documents of the Cross-Border Merger are hereby published in accordance with section 20I ΙΓ (2) of the Cyprus Companies Law, Cap. 113.
The General Meeting of the Disappearing Company that will examine and approve the Cross-Border Merger Plan and other relevant documents of the Cross-Border Merger has been set for the 19th of September 2025 at 10:00 at the Company’s registered office at 195, Lemesou, 2540, Dali, Nicosia, Cyprus.
Click below to download the relevant documents: